Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

New Strategies Using Antibody Combinations to Increase Cancer Treatment Effectiveness
Isabel Corraliza-Gorjón, Beatriz Somovilla-Crespo, Silvia Santamaría Santamaría, et al.
Frontiers in Immunology (2017) Vol. 8
Open Access | Times Cited: 63

Showing 1-25 of 63 citing articles:

Monoclonal Antibodies in Cancer Therapy
David J. Zahavi, Louis M. Weiner
Antibodies (2020) Vol. 9, Iss. 3, pp. 34-34
Open Access | Times Cited: 611
Engineered probiotics for local tumor delivery of checkpoint blockade nanobodies
Candice R. Gurbatri, Ioana Lia, Rosa L. Vincent, et al.
Science Translational Medicine (2020) Vol. 12, Iss. 530
Open Access | Times Cited: 412
GPCRomics: GPCR Expression in Cancer Cells and Tumors Identifies New, Potential Biomarkers and Therapeutic Targets
Paul A. Insel, Krishna Sriram, Shu Z. Wiley, et al.
Frontiers in Pharmacology (2018) Vol. 9
Open Access | Times Cited: 119
Insights Into Lung Cancer Immune-Based Biology, Prevention, and Treatment
Sara Saab, Hussein Zalzale, Zahraa Rahal, et al.
Frontiers in Immunology (2020) Vol. 11
Open Access | Times Cited: 96
Nanobody: A Small Antibody with Big Implications for Tumor Therapeutic Strategy
Shuyang Sun, Ziqiang Ding, Xiaomei Yang, et al.
International Journal of Nanomedicine (2021) Vol. Volume 16, pp. 2337-2356
Open Access | Times Cited: 92
Plant-Derived Anticancer Agents: Lessons from the Pharmacology of Geniposide and Its Aglycone, Genipin
Solomon Habtemariam, Giovanni Lentini
Biomedicines (2018) Vol. 6, Iss. 2, pp. 39-39
Open Access | Times Cited: 87
Triple negative breast cancer and non-small cell lung cancer: Clinical challenges and nano-formulation approaches
Saikat Ghosh, Ankit Javia, Saritha Shetty, et al.
Journal of Controlled Release (2021) Vol. 337, pp. 27-58
Closed Access | Times Cited: 66
Therapeutic Monoclonal Antibodies against Cancer: Present and Future
Marisa Delgado, José A. García‐Sanz
Cells (2023) Vol. 12, Iss. 24, pp. 2837-2837
Open Access | Times Cited: 31
Plant-derived Pembrolizumab in conjugation with IL-15Rα-IL-15 complex shows effective anti-tumor activity
Kaewta Rattanapisit, Pipob Suwanchaikasem, Christine Joy I. Bulaon, et al.
PLoS ONE (2025) Vol. 20, Iss. 1, pp. e0316790-e0316790
Open Access | Times Cited: 1
Advances in Antibody–Drug Conjugate Design: Current Clinical Landscape and Future Innovations
Laurence Gauzy‐Lazo, Ingrid Sassoon, Marie‐Priscille Brun
SLAS DISCOVERY (2020) Vol. 25, Iss. 8, pp. 843-868
Open Access | Times Cited: 60
Targeting CLDN18.2 by CD3 Bispecific and ADC Modalities for the Treatments of Gastric and Pancreatic Cancer
Guoyun Zhu, Davide Foletti, Xiaohui Liu, et al.
Scientific Reports (2019) Vol. 9, Iss. 1
Open Access | Times Cited: 51
Novel Human Anti-PD-L1 mAbs Inhibit Immune-Independent Tumor Cell Growth and PD-L1 Associated Intracellular Signalling
Margherita Passariello, Anna Morena D’Alise, Annachiara Esposito, et al.
Scientific Reports (2019) Vol. 9, Iss. 1
Open Access | Times Cited: 50
Potential of Anti-MUC1 Antibodies as a Targeted Therapy for Gastrointestinal Cancers
Mukulika Bose, Pinku Mukherjee
Vaccines (2020) Vol. 8, Iss. 4, pp. 659-659
Open Access | Times Cited: 45
Quantum leap of monoclonal antibody (mAb) discovery and development in the COVID-19 era
Simone Pecetta, Oretta Finco, Anja Seubert
Seminars in Immunology (2020) Vol. 50, pp. 101427-101427
Open Access | Times Cited: 45
Targeting Tumor‐Associated Antigens in Hepatocellular Carcinoma for Immunotherapy: Past Pitfalls and Future Strategies
Ligong Lu, Jun Jiang, Meixiao Zhan, et al.
Hepatology (2020) Vol. 73, Iss. 2, pp. 821-832
Closed Access | Times Cited: 36
Targeting a membrane-proximal epitope on mesothelin increases the tumoricidal activity of a bispecific antibody blocking CD47 on mesothelin-positive tumors
Eric Hatterer, Xavier Chauchet, Françoise Richard, et al.
mAbs (2020) Vol. 12, Iss. 1
Open Access | Times Cited: 33
Clinical Progress of PD-1/L1 Inhibitors in Breast Cancer Immunotherapy
Fei Chen, Naifei Chen, Yangyang Gao, et al.
Frontiers in Oncology (2022) Vol. 11
Open Access | Times Cited: 19
Targeted Therapies: The Role of Monoclonal Antibodies in Disease Management
Akram N. Salah, Amr H. Hashem, Mohamed Bakr Zaki, et al.
Journal of Biochemical and Molecular Toxicology (2025) Vol. 39, Iss. 2
Closed Access
Targeting of EGFR by a combination of antibodies mediates unconventional EGFR trafficking and degradation
Sylwia Jones, Peter King, Costin N. Antonescu, et al.
Scientific Reports (2020) Vol. 10, Iss. 1
Open Access | Times Cited: 28
Application of recombinant antibodies for treatment of Clostridioides difficile infection: Current status and future perspective
Hamideh Raeisi, Masoumeh Azimirad, Ali Nabavi-Rad, et al.
Frontiers in Immunology (2022) Vol. 13
Open Access | Times Cited: 18
Half-Life Extended Nanobody-Based CD38-Specific Bispecific Killercell Engagers Induce Killing of Multiple Myeloma Cells
Julia Hambach, William Fumey, Tobias Stähler, et al.
Frontiers in Immunology (2022) Vol. 13
Open Access | Times Cited: 14
Immunotherapy-based combination strategies for treatment of gastrointestinal cancers: current status and future prospects
Chenfei Zhou, Jun Zhang
Frontiers of Medicine (2019) Vol. 13, Iss. 1, pp. 12-23
Open Access | Times Cited: 19
Immune checkpoint inhibitor combination therapy for gastric cancer: Research progress (Review)
Xiaoxu Song, Weiwei Qi, Jing Guo, et al.
Oncology Letters (2020)
Open Access | Times Cited: 17
MUC1 Antibody-Based Therapeutics: The Promise of Cancer Immunotherapy
Mona Pourjafar, Pouria Samadi, Massoud Saidijam
Immunotherapy (2020) Vol. 12, Iss. 17, pp. 1269-1286
Closed Access | Times Cited: 16
Improving Biologics’ Effectiveness in Clinical Oncology: From the Combination of Two Monoclonal Antibodies to Oligoclonal Antibody Mixtures
Christel Larbouret, Laurent Gros, André Pèlegrin, et al.
Cancers (2021) Vol. 13, Iss. 18, pp. 4620-4620
Open Access | Times Cited: 15
Page 1 - Next Page

Scroll to top